AngioDynamics has announced it has received FDA clearance for a new peripherally inserted central catheter, according to a news release.
The company's BioFlo peripherally inserted central catheters features Endexo technology, which designed to help reduce the accumulation of catheter-related thrombus on, and in, the catheter, according to the company. These catheters are the first vascular access products from AngioDynamics to offer the BioFlo technology in the U.S. market. An initial launch is expected in the company's second quarter of fiscal year 2013.
"BioFlo technology provides AngioDynamics with a truly disruptive technology which we believe will drive increased demand for our vascular access products," said Joseph DeVivo, president and CEO of AngioDynamics, in the release. "With 15 percent of the $375 million U.S. PICC market, AngioDynamics holds a strong second position and BioFlo technology is positioned to help us grow that presence. BioFlo technology shows promise in decreasing the accumulation of catheter-related thrombus without incorporation of heparin, antibiotics, antimicrobials or any other transient materials typically associated with coated or impregnated technologies."
AngioDynamics is headquartered in Latham, N.Y.
Related Articles on FDA Clearances:
Symmetry Medical Receives FDA Clearance for FLASH PAK Evolution Valve
Covidien Receives FDA Clearance for Stapling System
Crospon Received FDA Clearance for EndoFLIP Gastroenterology Application